168 related articles for article (PubMed ID: 31164100)
1. Different EPHX1 methylation levels in promoter area between carbamazepine-resistant epilepsy group and carbamazepine-sensitive epilepsy group in Chinese population.
Lv Y; Zheng X; Shi M; Wang Z; Cui L
BMC Neurol; 2019 Jun; 19(1):114. PubMed ID: 31164100
[TBL] [Abstract][Full Text] [Related]
2. Association of ABCB1, CYP3A4, EPHX1, FAS, SCN1A, MICA, and BAG6 polymorphisms with the risk of carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in Chinese Han patients with epilepsy.
He XJ; Jian LY; He XL; Tang M; Wu Y; Xu YY; Sun XJ; Zhao LM
Epilepsia; 2014 Aug; 55(8):1301-6. PubMed ID: 24861996
[TBL] [Abstract][Full Text] [Related]
3. Effects of EPHX1, SCN1A and CYP3A4 genetic polymorphisms on plasma carbamazepine concentrations and pharmacoresistance in Chinese patients with epilepsy.
Yun W; Zhang F; Hu C; Luo X; Xue P; Wang J; Ge Y; Meng H; Guo Y
Epilepsy Res; 2013 Dec; 107(3):231-7. PubMed ID: 24125961
[TBL] [Abstract][Full Text] [Related]
4. Polymorphic Variants of SCN1A and EPHX1 Influence Plasma Carbamazepine Concentration, Metabolism and Pharmacoresistance in a Population of Kosovar Albanian Epileptic Patients.
Daci A; Beretta G; Vllasaliu D; Shala A; Govori V; Norata GD; Krasniqi S
PLoS One; 2015; 10(11):e0142408. PubMed ID: 26555147
[TBL] [Abstract][Full Text] [Related]
5. Effects of EPHX1 and CYP3A4*22 genetic polymorphisms on carbamazepine metabolism and drug response among Tunisian epileptic patients.
Chbili C; Fathallah N; Laouani A; Nouira M; Hassine A; Ben Amor S; Ben Ammou S; Ben Salem C; Saguem S
J Neurogenet; 2016 Mar; 30(1):16-21. PubMed ID: 27276192
[TBL] [Abstract][Full Text] [Related]
6. ABCB1 c.3435C > T and EPHX1 c.416A > G polymorphisms influence plasma carbamazepine concentration, metabolism, and pharmacoresistance in epileptic patients.
Zhang ML; Chen XL; Bai ZF; Zhao X; Li WX; Wang XY; Zhang H; Chen XF; Zhang SQ; Tang JF; Xiao XH; Zhao YL
Gene; 2021 Dec; 805():145907. PubMed ID: 34411648
[TBL] [Abstract][Full Text] [Related]
7. Influence of
Venkatraman S; Ramasamy K; Nair PP; Rajendran P
Drug Metab Pers Ther; 2023 Jun; 38(2):191-197. PubMed ID: 36853909
[TBL] [Abstract][Full Text] [Related]
8. Genetic polymorphisms of microsomal epoxide hydrolase and UDP-glucuronosyltransferase (UGT) and its effects on plasma carbamazepine levels and metabolic ratio in persons with epilepsy of South India: A cross-sectional genetic association study.
Venkatraman S; Ramasamy K; Nair PP
Indian J Pharmacol; 2023; 55(3):149-154. PubMed ID: 37555408
[TBL] [Abstract][Full Text] [Related]
9. Relevance of
Fricke-Galindo I; Jung-Cook H; Martínez-Juárez IE; Monroy-Jaramillo N; Ortega-Vázquez A; Rojas-Tomé IS; Dorado P; Peñas-Lledó E; Llerena A; López-López M
Pharmacogenomics; 2021 Oct; 22(15):983-996. PubMed ID: 34612084
[No Abstract] [Full Text] [Related]
10. Association between EPHX1 polymorphisms and carbamazepine metabolism in epilepsy: a meta-analysis.
Zhao GX; Shen ML; Zhang Z; Wang P; Xie CX; He GH
Int J Clin Pharm; 2019 Dec; 41(6):1414-1428. PubMed ID: 31650507
[TBL] [Abstract][Full Text] [Related]
11. Association of EPHX1 polymorphisms with plasma concentration of carbamazepine in epileptic patients: Systematic review and meta-analysis.
Hu T; Zeng X; Tian T; Liu J
J Clin Neurosci; 2021 Sep; 91():159-171. PubMed ID: 34373022
[TBL] [Abstract][Full Text] [Related]
12. Haplotype structures of EPHX1 and their effects on the metabolism of carbamazepine-10,11-epoxide in Japanese epileptic patients.
Nakajima Y; Saito Y; Shiseki K; Fukushima-Uesaka H; Hasegawa R; Ozawa S; Sugai K; Katoh M; Saitoh O; Ohnuma T; Kawai M; Ohtsuki T; Suzuki C; Minami N; Kimura H; Goto Y; Kamatani N; Kaniwa N; Sawada J
Eur J Clin Pharmacol; 2005 Mar; 61(1):25-34. PubMed ID: 15692831
[TBL] [Abstract][Full Text] [Related]
13. Effects of major transporter and metabolizing enzyme gene polymorphisms on carbamazepine metabolism in Chinese patients with epilepsy.
Zhu X; Yun W; Sun X; Qiu F; Zhao L; Guo Y
Pharmacogenomics; 2014; 15(15):1867-79. PubMed ID: 25495409
[TBL] [Abstract][Full Text] [Related]
14. Association of polymorphisms in EPHX1, UGT2B7, ABCB1, ABCC2, SCN1A and SCN2A genes with carbamazepine therapy optimization.
Hung CC; Chang WL; Ho JL; Tai JJ; Hsieh TJ; Huang HC; Hsieh YW; Liou HH
Pharmacogenomics; 2012 Jan; 13(2):159-69. PubMed ID: 22188362
[TBL] [Abstract][Full Text] [Related]
15. Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy.
Puranik YG; Birnbaum AK; Marino SE; Ahmed G; Cloyd JC; Remmel RP; Leppik IE; Lamba JK
Pharmacogenomics; 2013 Jan; 14(1):35-45. PubMed ID: 23252947
[TBL] [Abstract][Full Text] [Related]
16. Association between PK/PD-involved gene polymorphisms and carbamazepine-individualized therapy.
Ma CL; Jiao Z; Wu XY; Hong Z; Wu ZY; Zhong MK
Pharmacogenomics; 2015; 16(13):1499-512. PubMed ID: 26314341
[TBL] [Abstract][Full Text] [Related]
17. Effects of CYP3A4/5 and ABCB1 genetic polymorphisms on carbamazepine metabolism and transport in Chinese patients with epilepsy treated with carbamazepine in monotherapy and bitherapy.
Wang P; Yin T; Ma HY; Liu DQ; Sheng YH; Wang C; Zhou BT
Epilepsy Res; 2015 Nov; 117():52-7. PubMed ID: 26421491
[TBL] [Abstract][Full Text] [Related]
18. Effects of ABCB1 polymorphisms on plasma carbamazepine concentrations and pharmacoresistance in Chinese patients with epilepsy.
Meng H; Guo G; Ren J; Zhou H; Ge Y; Guo Y
Epilepsy Behav; 2011 May; 21(1):27-30. PubMed ID: 21493161
[TBL] [Abstract][Full Text] [Related]
19. Drug-resistant epilepsy in children with partial onset epilepsy treated with carbamazepine.
Aungaroon G; Holland KD; Horn PS; Standridge SM; Imming CM
Int J Neurosci; 2017 Oct; 127(10):849-853. PubMed ID: 27915489
[TBL] [Abstract][Full Text] [Related]
20. Association of MDR1 (C3435T) polymorphism and resistance to carbamazepine in epileptic patients from Turkey.
Ozgon GO; Bebek N; Gul G; Cine N
Eur Neurol; 2008; 59(1-2):67-70. PubMed ID: 17917461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
